Angela Blevins
Family Medicine · Parker, CONPI 1902564388
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $748, 2.6 times the $288 reported in 2022.
Across 95 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$315
- Pfizer$219
- Novo Nordisk$218
- Merck$141
- AstraZeneca$135
- Teva Pharmaceuticals USA, Inc.$126
- plus $694 from 16 others
What the payments were for
- Food & beverage$1,847100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $315 |
| Pfizer | 11 | $219 |
| Novo Nordisk | 12 | $218 |
| Merck | 8 | $141 |
| AstraZeneca | 6 | $135 |
| Teva Pharmaceuticals USA, Inc. | 6 | $126 |
| Lilly USA, LLC | 7 | $125 |
| Amgen(2 entities) | 6 | $113 |
| Exact Sciences | 4 | $72 |
| Neurocrine Biosciences, Inc. | 2 | $54 |
| Kowa Pharmaceuticals America, Inc. | 2 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Electromed, Inc. | 4 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Nevro Corp. | 1 | $29 |
| Organon | 2 | $25 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Alkermes, Inc. | 1 | $20 |
| Acerus Pharmaceuticals Corporation | 1 | $19 |
| GSK | 1 | $18 |
| Exeltis, USA Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
How this compares
$1,847 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 19 | $17,669 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,227 |
| Liothyronine Sodium | 17 | $595 |
| Np ThyroidThyroid,pork | 11 | $537 |
| Levothyroxine Sodium | 38 | $296 |
| Losartan Potassium | 55 | $261 |
| Valsartan | 14 | $251 |
| Atorvastatin Calcium | 11 | $250 |
| Celecoxib | 13 | $226 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $224 |
| Alprazolam | 32 | $152 |
| Metformin Hcl | 45 | $151 |
| Amlodipine Besylate | 42 | $148 |
| Zolpidem Tartrate | 29 | $144 |
| Lisinopril | 32 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $218 | $17,66919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Parker
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
- Paul SimmonsGrand Junction$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.